Novel catheter treatment of valve disease
$201,980ZIAFY2011HLNIH
National Heart, Lung, And Blood Institute
Investigators
Linked publications, trials & patents
Paper 39091280Paper 38533653Paper 37294000Paper 37086238Paper 36799217Paper 35879191Paper 35811698Paper 35738745Paper 35710281Paper 35668497Paper 35603621Paper 35580205Paper 35512920Paper 35378990Paper 35347844Paper 35272775Paper 34652290Paper 34009283Paper 34003670Paper 33958168Paper 33952312Paper 33888242Paper 33860962Paper 33663781Paper 33575191Paper 33358650Paper 32902101Paper 32513014Paper 32385950Paper 32305393Paper 32216915Paper 32198594Paper 32192701Paper 32159289Paper 31272666Paper 31257172Paper 31202947Paper 31136789Paper 31118146Paper 31088121Paper 31078183Paper 30846083Paper 30841903Paper 30772294Paper 30598902Paper 30527166Paper 30409286Paper 30286861Paper 30230211Paper 29969430Paper 29929643Paper 29778867Paper 29737030Paper 29622147Paper 29605244Paper 29405564Paper 29314639Paper 28940991Paper 28805039Paper 28774381Paper 28471059Paper 28427597Paper 28335897Paper 28057275Paper 27989885Paper 27940959Paper 27609260Paper 27209112Paper 27085581Paper 27053637Paper 26618198Paper 26438770Paper 26408210Paper 26356244Paper 26205455Paper 26022536Paper 25703872Paper 25614432Paper 25510917Paper 25459598Paper 25315516Paper 24814495Paper 24530198Paper 24038978Paper 23870697Paper 23500317Paper 23464334Paper 23331459Paper 22855740Paper 22707441Paper 22128071Paper 19660696Patent 9579200Patent 10123768
Abstract
We are continuing development of this novel catheter technique, which establishes circumferential tension around the mitral valve annulus by exploiting both natural (coronary venous) and un-natural (intramyocardial septal) trajectories. We have established proof-of-principal in a porcine model of ischemic cardiomyopathy that cerclage annuloplasty reduces secondary ("functional") mitral valve regurgitation. We have developed new catheter designs to simplify the procedure. We are attempting to reduce the demands on image guidance for the procedure. We are assembling resources toward Investigational Device Exemption clinical protocols.
View original record on NIH RePORTER →